

## ORIGINALARBEITEN

1. H. Kaesemann, H. Caffier, F.J. Hoffmann, G. Crombach, H. Würz, R. Kreienberg, V. Möbus, P. Schmidt-Rhode, G. Sturm:  
Monoklonale Antikörper in Diagnostik und Verlaufskontrolle des Ovarialkarzinoms. CA 125 als Tumormarker.  
Klin. Wochenschr. 64 (1986) 781-785
2. G. Bartzke, H. Rössler, R. Seufert, V. Möbus, R. Kreienberg:  
Resultate der Tumorresistenz-Testung (in vitro - in vivo) bei Mammakarzinomen.  
Geburtsh. u. Frauenheilk. 47 (1987) 690-694
3. G. Crombach, H. Würz, R. Kreienberg, V. Möbus, P. Schmidt-Rhode, G. Sturm, H. Caffier, H. Kaesemann:  
Evaluation of SCC Antigen as a Tumor Marker for Cervical Cancer - a Cooperative Study of the GTMG.  
J. of Tumor Marker Oncology 3 (1988) 59-63
4. V. Möbus, R. Kreienberg, G. Crombach, H. Würz, H. Caffier, H. Kaesemann, F.J. Hoffmann, P. Schmidt-Rhode, G. Sturm, M. Kaufmann:  
Evaluation of Ca 125 as a Prognostic and Predictive Factor in Ovarian Cancer.  
J. of Tumor Marker Oncology 3 (1988) 251-258
5. G. Crombach, H. Würz, F. Herrmann, R. Kreienberg, V. Möbus, P. Schmidt-Rhode, G. Sturm, H. Caffier, H. Kaesemann:  
Bedeutung des SCC-Antigens in der Diagnostik und Verlaufskontrolle des Zervixkarzinoms.  
Dtsch. Med. Wschr. 114 (1989) 700-705
6. F. Casper, V. Möbus, S. Wellek, D. Gehm, R. Seufert, P. Brockerhoff, R. Kreienberg:  
Der Stellenwert pathologischer Alpha-1-Fetoprotein-Konzentrationen im Rahmen der pränatalen Diagnostik.  
Z. Geburtsh. u. Perinat. 196 (1992) 7-10
7. V. Möbus, F. Casper, G. Heintz, R. Kreienberg, P. Brockerhoff:  
Amniocentese zur pränatalen Diagnostik aus psychischer Indikation.  
Geburtsh. u. Frauenheilk. 52 (1992) 225-229
8. V. Möbus, C.-D. Gerharz, U. Press, R. Moll, T. Beck, W. Mellin, K. Pollow, P.G. Knapstein, R. Kreienberg:  
Morphological, immunohistochemical and biochemical characterization of six newly established human ovarian carcinoma cell lines.  
Int. J. Cancer 52 (1992) 76-84
9. R. Kreienberg, V. Möbus:  
Tumormarker in der Gynäkologie.  
Lab. med. 16 (1992) 21-26
10. G. Crombach, A. Ingenhorst, W.-J. Göhring, V. Möbus, D. Peters, H.-J. Schaeffer, A. Bolte:  
Cathepsin D Concentrations in the Cytosol of Benign and Malignant Tumors of the Breast and the Female Genital Tract.

Tumordiagn. & Ther. 13 (1992) 14-18

11. W. Weikel, A. Kleinmann, T. Beck, M. Mitze, V. Möbus, R. Kreienberg:  
Immunhistochemischer Nachweis von CEA und CA 15-3 bei Mammakarzinomen: Vergleich zu serologischen Untersuchungen und Prognosefaktoren.  
Tumordiagn. & Ther. 13 (1992) 178-186
12. T. Beck, V. Möbus, M. Mahlke, P.G. Knapstein:  
Mayer-Rokitansky-Küster-Syndrom: Möglichkeiten und Ergebnisse operativer Korrektur der angeborenen Vaginalaplasie.  
Sexualmedizin 21 (1992) 186-192
13. K. Pollow, M. Juchem, W. Elger, N. Jacobi, G. Hoffmann, V. Möbus:  
Dihydrospirorenone (ZK30595): A novel synthetic progestagen - characterization of binding to different receptor proteins.  
Contraception 46 (1992) 561-574
14. V. Möbus, J. Paula, T. Beck, G. Crombach, R. Kreienberg:  
Tumormarkerverläufe zur Beurteilung der Effektivität einer Chemo- oder Hormontherapie beim metastasierenden Mammakarzinom.  
Geburtsh. u. Frauenheilk. 53 (1993) 24-29
15. M. Juchem, K. Pollow, W. Elger, N. Jacobi, G. Hoffmann, V. Möbus:  
Receptor binding of Norgestimate - A new orally active synthetic progestational compound.  
Contraception 47 (1993) 283-294
16. V. Möbus, C.-D. Gerharz, M. Mitze, R. Moll, K. Pollow, T. Kother, P.-G. Knapstein, R. Kreienberg:  
Establishment and Characterization of Six New Human Endometrial Adenocarcinoma Cell Lines.  
Gynecol. Oncol. 48 (1993) 370-383
17. V. Möbus, K. Sachweh, P.-G. Knapstein, R. Kreienberg:  
Frauen nach operativ korrigierter Vaginalaplasie: Eine Nachuntersuchung zur psychosexuellen Rehabilitation.  
Geburtsh. u. Frauenheilk. 53 (1993) 125-131
18. V. Möbus, M. Kretz, W. Asphal, R. Kreienberg:  
Detection of P-Glycoprotein 170 in Ovarian Carcinoma Cell Lines and Enhancement of Its Expression after Induction of in vitro Resistance.  
Onkologie 16 (1993) 114-120
19. L. A. Berti, S.O. Hoffmann, V. Möbus:  
"Traditioneller" vs. "Modifizierter" Forschungsansatz im Rahmen psychoonkologischer Studien.  
PPmP 43 (1993) 151-158
20. V. Möbus, W. Asphal, P.-G. Knapstein, R. Kreienberg:  
Effects of Interferon-gamma on the proliferation and modulation of cell surface structures of human ovarian carcinoma cell lines.  
J. Cancer Res. Clin. Oncol. 120 (1993) 27-34

21. V. Möbus, W. Weikel, R. Kreienberg:  
Sekretionsverhalten der Tumormarker CA-125 und TPS bei humanen permanenten Ovarialzelllinien.  
Tumordiagn. u. Ther. 14 (1993) 181-186
22. V. Möbus, T. Kother, D. Kieback, G. Crombach, R. Kreienberg:  
Untersuchungen zur Wirksamkeit von Cisplatin und Carboplatin an permanenten humanen Ovarialkarzinomzelllinien.  
Tumordiagn. u. Ther. 14 (1993) 132-137
23. V. Möbus, F. Casper, G. Heintz, R. Kreienberg, P. Brockerhoff:  
Amniocentese aus psychischer Indikation.  
Die Hebamme 6 (1993) 15-18
24. F. Casper, V. Möbus, R. Seufert, P. Brockerhoff, R. Kreienberg:  
Alpha-1-Fetoproteinkonzentrationen in der pränatalen Diagnostik.  
Die Hebamme 6 (1993) 54-56
25. M. Stoeck, C. Marland-Noske, M. Manasterski, R. Zawatzky, S. Horn, V. Möbus, P. Schlag, V. Schirmmacher:  
In vitro expansion and analysis of T lymphocyte microcultures obtained from the vaccination sites of cancer patients undergoing active specific immunization with autologous Newcastle-disease-virus-modified tumour cells.  
Cancer Immunol. Immunother. 37 (1993) 240-244
26. V. Möbus, R. Mucbe, W. Gaus:  
Replik zur Kritik von Prof. Kürzl und Prof. Kuß.  
Geburtsh. u. Frauenheilk. 53 (1993) 588-589
27. D.G. Kieback, I.B. Runnebaum, V. Möbus, R. Kreienberg, S.K. McCamant, C.L. Edwards, L.A. Jones, M.-Y. Tsai, B.W. O'Malley:  
Chicken Ovalbumin Upstream Promoter Transcription Factor (COUP-TF): An Orphan Steroid Receptor with a Specific Pattern of Differential Expression in Human Ovarian Cancer Cell Lines.  
Gynecol. Oncol. 51 (1993) 167-170
28. V. Möbus, S. Horn, M. Stöck, V. Schirmmacher:  
Tumor Cell Vaccination for Gynecological Tumors.  
Hybridoma 12 (5), (1993) 543-547
29. R.P. Baum, A.A. Noujaim, A. Nanci, V. Möbus, A. Hertel, A. Niesen, B. Donnerstag, T. Sykes, G. Boniface, G. Hör:  
Clinical Course of Ovarian Cancer Patients Under Repeated Stimulation of HAMA Using MAb OC 125 and B43.13  
Hybridoma 12 (5), (1993) 583-589
30. G. Crombach, A. Ingenhorst, U.-J. Göhring, A. Scharl, W. Neuhaus, V. Möbus, H.J. Schaeffer:  
Expression of pS2 protein in breast cancer.  
Arch. Gynecol. Obstet. 253 (1993) 183-192
31. S. Wilhelm, O. Wilhelm, M. Schmitt, V. Möbus, R. Kreienberg, H. Graeff:  
Expression of the cell surface receptor for thrombin, thrombomodulin, in human ovarian cancer cells.  
Gynäkol. Geburtshilfliche Rundsch. 33 Suppl 1 (1993) 202-203

32. D.G. Kieback, M.F. Press, E.N. Atkinson, V.J. Möbus, I.B. Runnebaum, R. Kreienberg, L.A. Jones:  
Prognostic Significance of Estrogen Receptor Expression in Ovarian Cancer. Immuno-reactive Score (IRS) vs. Composition Adjusted Receptor Level (CARL).  
*Anticancer Research*, 13 (1993) 2489-2496
33. V. Möbus, R. Moll, C.-D. Gerharz, D.G. Kieback, G. Hoffmann, R. Kreienberg:  
Establishment of new ovarian and colon carcinoma cell lines: Differentiation is only possible by cytokeratin analysis.  
*Br. J. Cancer* 69 (1994) 422-428
34. I.B. Runnebaum, X.-W. Tong, V. Möbus, V. Heilmann, D.G. Kieback, R. Kreienberg:  
Multiplex PCR (MPCR) screening detects small p53 deletions and insertions in human ovarian cancer cell lines.  
*Human Genetics* 93 (1994) 620-624
35. C. Will, O. Wilhelm, S. Höhl, V. Möbus, U. Weidle, R. Kreienberg, F. Jänicke, M. Schmitt, H. Graeff:  
Expression of Urokinase-Type Plasminogen Activator (uPA) and its Receptor (UPAR) in Human Ovarian Cancer Cells and In Vitro Invasion Capacity.  
*Int. J. Oncol.* 5 (1994) 753-761
36. W. Weikel, E. Wellens, C. Brumm, V. Möbus, T. Beck, M. Mitze:  
Immunohistochemischer und serologischer Nachweis von CEA und CA 125 an Ovarialkarzinomen.  
*Tumordiagn. u. Ther.* 15 (1994) 134-142
37. E.M.J. Schutter, P. Kenemans, C. Sohn, P. Kristen, G. Crombach, R. Westermann, V. Möbus, M. Kaufmann, H. Caffier, P. Schmidt-Rhode, R. Kreienberg, R.A. Verstraeten, F. Cornillie:  
Diagnostic Value of Pelvic Examination, Ultrasound, and Serum CA 125 in Postmenopausal Women with a Pelvic Mass.  
*Cancer* 74 (1994) 1398-1406
38. I.B. Runnebaum, X.W. Tong, V.J. Möbus, D.G. Kieback, H.E. Rosenthal, R. Kreienberg:  
p53 mutant His<sup>175</sup> identified in a newly established fallopian tube carcinoma cell line secreting interleukin 6.  
*FEBS-Letters* 353 (1994) 29-32
39. T. Beck, F. Bahlmann, V. Möbus:  
Histometric Investigations of Placental Villi in Cases of Unexpected Fetal Acidosis.  
*J. Perinat. Med.* 22 (1994) 309-317
40. V. Möbus, I. Runnebaum, D.G. Kieback, R. Kreienberg:  
Vaginaler Fremdkörper (Zange) als Zufallsbefund anlässlich der Primäroperation eines Mammakarzinomes.  
*Geburtsh. u. Frauenheilk.* 55 (1995) 233-234
41. D.G. Kieback, M.F. Press, S.K. McCamant, E.N. Atkinson, V.J. Möbus, I.B. Runnebaum, R. Kreienberg, L.A. Jones:  
Die prognostische Differenzierung von Ovarialkarzinomen durch immunzytochemische Analyse der Östrogenrezeptorexpression.

- Geburtsh. u. Frauenheilk. 55 (1995) 189-194
42. V. Möbus, R. Kreienberg:  
Das Ovarialkarzinom: Standards in Operation, Chemotherapie und Nachsorge.  
Der Mediziner 4 (1995) 50-52
  43. I.B. Runnebaum, S. Maier, X.W. Tong, H.E. Rosenthal, V.J. Möbus, D.G. Kieback, R. Kreienberg:  
Human papillomavirus integration is not associated with advanced epithelial ovarian cancer in german patients.  
Cancer Epidemiology, Biomarkers and Prevention 4 (1995) 573-575
  44. R. Kreienberg, V. Möbus:  
Früherkennung von Zervix- und Korpuskarzinomen.  
Onkologie 18 (1995) 41-45
  45. H.-G. Meerpohl, A. du Bois, H. Kühnle, H.-J. Lück, R. Kreienberg, V. Möbus, Th. Bauknecht, O. Köchli, H. Bochtler, K. Diergarten, A. Heuser:  
Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.  
Sem. Oncol. 22, Suppl 15 (1995) 7-12
  46. V. Möbus, K. Kortenhorn, R. Kreienberg, V. Friedberg:  
Long-term results after operative correction of vaginal aplasia.  
Am. J. Obstet. Gynecol. 175 (1996) 617-624
  47. R. Kreienberg, V. Möbus:  
Adjuvante Chemotherapie des nodal negativen Mammakarzinomes.  
Gynäkologe 29 (1996) 233-241
  48. I.B. Runnebaum, D.G. Kieback, V. Möbus, X.-W. Tong, R. Kreienberg:  
Subcellular localization of accumulated p53 in ovarian cancer cells.  
Gynecol. Oncol. 61 (1996) 266-271
  49. V. Möbus:  
Hochdosis-Chemotherapie: Eine Übersicht beim Ovarial-Karzinom.  
Zentralbl. Gynäkol. 118 (1996) 573-574
  50. D.G. Kieback, T. Levi, P. Kohlberger, U. Friedrich, M.F. Press, H.E. Rosenthal, V.J. Möbus, I.B. Runnebaum, X.-W. Tong, M.-J. Tsai:  
Chicken Ovalbumin Upstream Promoter-Transcription Factor (COUP-TF): Expression in Human Endometrial Cancer Cell Lines.  
Anticancer Research 16 (1996) 3371-3376
  51. V.J. Möbus, R. Stein, D.G. Kieback, I.B. Runnebaum, G. Sass, R. Kreienberg:  
Antitumor Activity of New Organometallic Compounds in Human Ovarian Cancer Cell Lines and Comparison to Platin Derivatives.  
Anticancer Research 17 (2) (1997) 815-822
  52. V. Möbus, T. Volm, R. Kreienberg:  
Welche Aussichten ergeben sich durch neuere Chemotherapeutika beim Ovarialkarzinom?  
Der Gynäkologe 30 (1997) 108-117

53. A. duBois, H.-J. Lück, T. Bauknecht, V. Möbus, H. Bochtler, K. Diergarten, H.G. Meerpohl:  
Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer.  
Ann. Oncol. 8 (1997) 355-361
54. U. Nitz, M. Frick, A. Adomeit, C. Jackisch, A. Schwenkhagen, V. Möbus, H.G. Bender:  
Stammzellgestützte Hochdosischemotherapie (HDCT) in der Behandlung gynäkologischer Malignome: Indikationen und aktuelle Studienlage in der Bundesrepublik Deutschland.  
Zentralbl. Gynäkol. 119 (1997) 195-203
55. V. Möbus, C. v. Schilling, R. Kreienberg, N. Frickhofen, F. Herrmann:  
High-dose chemotherapy with autologous haematopoietic stem cell support in advanced ovarian cancer.  
Onkologie 20 (1997) 196-202
56. E. Stickeler, I.B. Runnebaum, V.J. Möbus, D.G. Kieback, R. Kreienberg:  
Expression of CD44 Standard and Variant Isoforms v5, v6 and v7 in Human Ovarian Cancer Cell Lines.  
Anticancer Research, 17 (1997) 1871-1876
57. A. duBois, H.-J. Lück, W. Meier, V. Möbus, S. Costa, B. Richter, T. Bauknecht, M. Warm, W. Schröder, S. Olbricht, U. Nitz, C. Jackisch, for the German AGO Study Group Ovarian Cancer:  
Carboplatin Plus Paclitaxel as First-Line Chemotherapy in Previously Untreated Advanced Ovarian Cancer.  
Semin. Oncol. 24 (Suppl 11) (1997) S11-28-S11-33
58. H.G. Meerpohl, A. duBois, H.-J. Lück, H. Kühnle, V. Möbus, R. Kreienberg, T. Bauknecht, O. Köchli, H. Bochtler, K. Diergarten:  
Paclitaxel Combined With Carboplatin in the First-Line Treatment of Advanced Ovarian Cancer: A Phase I Trial.  
Semin. Oncol. 24, (1 Suppl 2) (1997) S2-17-S2-22
59. A. duBois, H.-J. Lück, W. Meier, V. Möbus, S. Costa, B. Richter, M. Warm, T. Bauknecht, W. Schröder, S. Olbricht, U. Nitz, C. Jackisch:  
Carboplatin/Paclitaxel Versus Cisplatin/Paclitaxel as First-Line Chemotherapy in Advanced Ovarian Cancer: An Interim Analysis of a Randomized Phase III Trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.  
Semin. Oncol. 24 (Suppl 15) (1997) S15-44-S15-52
60. E. Stickeler, V.J. Möbus, D.G. Kieback, P. Kohlberger, I.B. Runnebaum, R. Kreienberg:  
Intron 9 Retention in Gene Transcripts Suggests Involvement of CD44 in the Tumorigenesis of Ovarian Cancer.  
Anticancer Research 17 (1997) 4395-4398
61. E.M.J. Schutter, C. Sohn, P. Kristen, V. Möbus, G. Crombach, M. Kaufmann, H. Caffier, R. Kreienberg, A.A. Verstraeten, P. Kenemans:  
Estimation of Probability of Malignancy Using a Logistic Model Combining Physical Examination, Ultrasound, Serum CA 125 and Serum CA 72-4 in Postmenopausal Women with a Pelvic Mass. An International Multicenter Study.  
Gynecol. Oncol. 69 (1998) 56-63

62. V. Möbus, R. Kreienberg:  
Systemische Therapie des Zervixkarzinoms.  
Der Onkologe 4 (1998) 167-173
63. V. Möbus, R. Moll, C.D. Gerharz, D.G. Kieback, I.B. Runnebaum, S. Linner, L. Dreher, H.-J. Grill, R. Kreienberg:  
Differential Characteristics of Two New Tumorigenic Cell Lines of Human Breast Carcinoma Origin.  
Int. J. Cancer 77 (1998) 415-423
64. T. Levy, I. Agoulnik, E.N. Atkinson, X.W. Tong, H.M. Gause, A. Hasenburg, I.B. Runnebaum, E. Stickeler, V.J. Möbus, A.L. Kaplan, D.G. Kieback:  
Telomere length in human white blood cells remains constant with age and is shorter in breast cancer patients.  
Anticancer Res. 18 (1998) 1345-1349
65. N. Frickhofen, R. Kreienberg, L. Bergmann, V. Möbus:  
Hochdosistherapie des fortgeschrittenen Ovarialkarzinoms.  
Der Onkologe 4 (1998) 1140-1146
66. V. Möbus, A. du Bois:  
Aktuelle Studien zur Therapie des Ovarialkarzinoms in den USA und in Europa.  
Der Onkologe 4 (1998) 1168-1171
67. U. Nitz, D. Wallwiener, V. Möbus:  
Stammzellgestützte Hochdosismethotherapie (HDCT) in der gynäkologischen Onkologie 1998.  
Frauenarzt 39 (1998) 1492-1498
68. V. Möbus, P.N. Pfaff, R. Kreienberg:  
Topotecan (Hycamtin) in the Therapy of Recurrent Ovarian Carcinoma  
Onkologie 21 (suppl) (1998) 2-5
69. T. Volm, V. Möbus, R. Kreienberg:  
New Aromatase Inhibitors.  
Onkologie 21 (1998) 460-466
70. V. Möbus, C. von Schilling, R. Kreienberg, M. Wiesneth, L. Bergmann, N. Frickhofen:  
Stammzellgestützte Hochdosismethotherapie (HDCT) in der Primärbehandlung des fortgeschrittenen Ovarialkarzinomes.  
Schweiz. Rundsch. Med. Prax. 88 (1999) 507-511
71. T. Volm, V. Möbus, P. Pfaff, R. Kreienberg:  
Infektionen unter Chemotherapie.  
Der Gynäkologe 32 (1999) 529-539
72. V. Möbus:  
Adjuvante Behandlung des Mammakarzinoms: Überlebensvorteil durch neue Therapiekonzepte.  
Der Onkologe 5 (Suppl 1) (1999) S 1- S 4
73. V. Möbus  
Erfahrungen mit Caelyx® in der Therapie des metastasierten Mammakarzinoms.  
Onkologie 23 (Suppl. 2) (2000) 20-25

74. V. Möbus:  
Adjuvante Chemotherapie des Mammakarzinoms: Wirksamkeit korreliert mit dem Menopausenstatus.  
Z. Onkol./J. of Oncol. 32 (2000) 65-71
75. E. Stickeler, F.D. Vogl, T. Denkinger, V.J. Möbus, R. Kreienberg, I.B. Runnebaum:  
Soluble CD44 splice variants and pelvic lymph node metastasis in ovarian cancer patients.  
Int. J. Mol. Med. 6 (2000) 595-601
76. V. Möbus:  
Risk-Adapted Chemotherapy in the Adjuvant Setting of Breast Cancer.  
Onkologie 23 (2000) 200-201
77. V. Möbus:  
Adjuvante Therapie des Mammakarzinoms.  
Der Onkologe 6 (Suppl. 1) (2000) S5 – S8
78. A. Brüning, T. Köhler, S. Quist, S. Wang-Gohrke, V.J. Möbus, R. Kreienberg, I.B. Runnebaum:  
Adenoviral Transduction Efficiency of Ovarian Cancer Cells Can Be Limited by Loss of Integrin  $\beta_3$  Subunit Expression and Increased by Reconstitution of Integrin  $\alpha_v\beta_3$   
Hum. Gene Ther. 12 (2001) 391-399
79. U. Wagner, S. Köhler, S. Reinartz, P. Giffels, J. Huober, K. Renke, H. Schlebusch, H.-J. Biersack, V. Möbus, R. Kreienberg, T. Bauknecht, D. Krebs, D. Wallwiener:  
Immunological Consolidation of Ovarian Carcinoma Recurrences with Monoclonal Anti-idiotypic Antibody ACA 125: Immune Responses and Survival in Palliative Treatment.  
Clin. Cancer Res. 7 (2001) 1154-1162
80. A. du Bois, H.J. Lück, J. Pfisterer, W. Schroeder, J.U. Blohmer, R. Kimmig, V. Moebus, J. Quaas:  
2nd -line chemotherapy with carboplatin and gemcitabine in patients with platinum sensitive recurrent ovarian cancer – A phase I/II study of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group.  
Ann. Oncol. 12 (2001) 1115-1120
81. V. Möbus, C.D. Gerharz, W. Weikel, O. Merk, L. Dreher, R. Kreienberg, R. Moll:  
Characterization of a human carcinosarcoma cell line of the ovary established after in-vivo change of histologic differentiation.  
Gynecol. Oncol. 83 (2001) 523-532
82. V. Möbus, C. Uleer, R. Kreienberg:  
Systemische Therapie des Zervixkarzinoms.  
Onkologie 7 (2001) 880-888
83. E. Stickeler, S. Therasakvichya, V.J. Moebus, D.G. Kieback, I.B. Runnebaum, R. Kreienberg:  
Modulation of soluble CD44 concentrations by hormone and anti-hormone treatment in gynecologic tumor cell lines.  
Oncol Rep 8 (2001) 1381-1386
84. V. Möbus, P. Pfaff, T. Volm, R. Kreienberg, S. Kaubitzsch:  
Long time therapy with topotecan in patients with recurrence of ovarian carcinoma.

85. H.-J. Lück, A. duBois, B. Weber, J. Pfisterer, A. Goupil, W. Kuhn, J.C. Barats, J. Blohmer, M. Mousseau, W. Schröder, V. Möbus, B. Richter:  
The integration of anthracyclines in the treatment of advanced ovarian cancer.  
Int. J. Gynecol. Cancer 11 (Suppl 1) (2001) 34-38
86. G. v. Minckwitz, K. Brunnert, S.D. Costa, K. Friedrichs, C. Jackisch, B. Gerber, N. Harbeck, H. Junkermann, V. Möbus, U. Nitz, G. Schaller, A. Scharl, C. Thomssen, M. Untch:  
Evidence-based recommendations on primary treatment of carcinomas of the breast.  
Zentralbl. Gynaekol. 124(5) (2002) 293-303
87. M. Oppitz, V. Möbus, S. Brock, U. Drews:  
Muscarinic Receptors in Cell Lines from Ovarian Carcinoma: Negative Correlation with Survival of Patients.  
Gynecol. Oncol. 85 (2002) 159-164
88. A. du Bois, W. Meier, H.J. Lück, G. Emons, V. Möbus, W. Schroeder, S. Costa, T. Bauknecht, S. Olbricht, C. Jackisch, B. Richter, U. Wagner:  
Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer.  
Ann. Oncol. 13 (2002) 251-257
89. G. v. Minckwitz, K. Brunnert, S.D. Costa, K. Friedrichs, C. Jackisch, B. Gerber, N. Harbeck, H. Junkermann, V. Möbus, U. Nitz, G. Schaller, A. Scharl, C. Thomssen, M. Untch:  
AGO-Empfehlung: Primärbehandlung von Mammakarzinomen.  
Frauenarzt 43 (2002) 920-931
90. V. Möbus, R.P. Baum, B. Schultes, M. Bolle, C. Nicodemus:  
Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer.  
Am. J. Obstet. Gynecol. 189 (2003) 28-36
91. A. du Bois, H.-J. Lück, W. Meier, H.-P. Adams, V. Möbus, S.D. Costa, T. Bauknecht, B. Richter, M. Warm, W. Schröder, S. Olbricht, U. Nitz, C. Jackisch, G. Emons, U. Wagner, W. Kuhn, J. Pfisterer:  
A Randomized Clinical Trial of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel as First line Treatment of Ovarian Cancer FIGO.  
J. Natl. Cancer Inst. 95 (2003) 1320-1329
92. A.R. Zander, N. Kröger, C. Schmoor, W. Krüger, V. Möbus, N. Frickhofen, B. Metzner, W. Schultze, W.E. Berdel, M. Königsman, E. Thiel, H. Wandt, K. Possinger, L. Trümper, R. Kreienberg, M. Carstensen, A. Franke, E.H. Schmidt, F. Jänicke, M. Schumacher, W. Jonat on behalf of the German Breast Cancer Study Group (GABG):  
High-Dose Chemotherapy with Autologous Haematopoietic Stem-Cell Support (HSCS) vs. Standard-Dose Chemotherapy in Breast Cancer Patients with 10 or more Positive Lymph Nodes: First Results of a Randomized Trial.  
J. Clin. Oncol. 22 (2004) 2273-2283
93. N. Harbeck, V. Möbus, C. Thomssen, C. Jackisch:  
Adjuvante Chemotherapie beim primären Mammakarzinom: Standard und Optionen 2003

Gynäkol. Prax. 28 (2004) 285-290

94. G.E. Konecny, C. Thomssen, H.-J. Lück, M. Untch, H.-J. Wang, W. Kuhn, H. Eidtmann, A. duBois, S. Olbricht, D. Steinfeld, V. Möbus, G. v. Minckwitz, S. Dandekar, L. Ramos, G. Pauletti, M. Pegram, F. Jänicke, D.J. Slamon:  
HER-2/neu Gene Amplification and Response to Paclitaxel in Patients with Metastatic Breast Cancer  
J. Natl. Cancer Inst. 96 (2004) 1141-1151
95. W. Janni, G.v. Minckwitz, V. Möbus, E. Solomayer, C. Jackisch, U. Nitz, B. Gerber:  
Adjuvante Chemotherapie des Mammakarzinoms-Gravenbruch 2004-11-25 Frauenarzt 45 (2004) 816-822
96. V. Müller, I. Witzel, H.J. Lück, G. Köhler, G.v. Minckwitz, V. Möbus, D. Sattler, W. Wilczak, T. Löning, F. Jänicke, K. Pantel, C. Thomssen:  
Prognostic and predictive impact of the HER-2/neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.  
Breast Cancer Res. Tr. 86 (2004) 9-18
97. V. Möbus und E. Böhm:  
Adjuvante Therapie bei Patientinnen unter 35 Jahren.  
Onkologie heute 4 (2004) 24-30
98. S. Reinartz, S. Kohler, H. Schlebusch, K. Krista, P. Giffels, K. Renke, J. Huober, V. Möbus, R. Kreienberg, A. duBois, P. Sabbatini, U. Wagner:  
Vaccination of patients with advanced ovarian carcinoma with the anti-idiotypic ACA 125: immunological response and survival (phase Ib/II).  
Clin. Cancer Res. 10 (2004) 1580-1587
99. C. Moisisidis and V. Möbus:  
Erythema multiforme major following Docetaxel  
Arch. Gynecol. Obstet. 271 (2005) 267-269
100. N.I. Euer, S. Kaul, H. Deissler, V.J. Möbus, R. Zeillinger, U.H. Weidle:  
Identification of L1CAM, Jagged2 and Neuromedin U as ovarian cancer-associated antigens.  
Oncol. Rep. 13 (2005) 375-387
101. V. Möbus, R. Kreienberg:  
Adjuvante Chemotherapie beim Mammakarzinom.  
Gynäkologe 38 (2005) 416-424
102. Pils D, Horak P, Gleiss A, Sax C, Fabjani G, Moebus VJ, Zielinski C, Reinthaller A, Zeillinger R, Krainer M: Five genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival.  
Cancer 104 (2005),2417-2429
103. Pfisterer J, Weber B, Reuss A, Kimmig R, du Bois A, Wagner U, Bourgeois H, Meier W, Costa S, Blohmer JU, Lortholary A, Olbricht S, Stähle A, Jackisch C, Hardy-Bessard AC, Möbus V, Quaas J, Richter B, Schröder W, Geay JF, Lück HJ, Kuhn W, Meden H, Nitz U, Pujade-Lauraine E; AGO-OVAR; GINECO. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.

- J Natl. Cancer Inst. 98 (2006), 1036-1045
104. Huober J, Jackisch C, Untch M, Möbus V, Wallwiener D, Kaufmann M, Minckwitz G. Adjuvant therapy with trastuzumab (Herceptin) in primary breast cancer. Zentralbl Gynakol. 128 (2006), 30-37
  105. Frickhofen N, Berdel WE, Opri F, Haas R, Schneeweiss A, Sandherr M, Kuhn W, Hossfeld DK, Thomssen C, Heimpel H, Kreienberg R, Hinke A, Möbus V; German Study Groups Arbeitsgemeinschaft Internistische Onkologie (AIO); Arbeitsgemeinschaft Gynäkologische Onkologie (AGO). Phase I/II trial of multicycle high-dose chemotherapy with peripheral blood stem cell support for treatment of advanced ovarian cancer. Bone Marrow Transplant. 38 (2006), 493-499
  106. Mustea A, Sehouli J, Fabjani G, Koensgen D, Möbus V, Braicu EI, Pirvulescu C, Thomas A, Tong D, Zeillinger R. Epidermal growth factor receptor (EGFR) mutation does not correlate with platinum resistance in ovarian carcinoma. Results of a prospective pilot study. Anticancer Res. 27 (2007), 1527-1530
  107. Möbus V, Kieback DG, Kaubitzsch SK: Duration of chemotherapy with topotecan influences survival in recurrent ovarian cancer: a meta-analysis. Anticancer Res. 27 (2007), 1581-1587
  108. Möbus V, Wandt H, Frickhofen N, Bengala C, Champion K, Kimmig R, Ostermann H, Hinke A, Ledermann JA: Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. J Clin Oncol. 25 (2007):4187-93.
  109. Untch M, Bergh J, Citron M, Hudis CA, Huober J, Möbus V, Steger G. Dose-Dense Therapy. Breast Care (Basel) 3,(2008):134-138.
  110. Zander AR, Schmoor C, Kröger N, Krüger W, Möbus V, Frickhofen N, Metzner B, Berdel WE, Koenigsmann M, Thiel E, Wandt H, Possinger K, Kreienberg R, Schumacher M, Jonat W: Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up. Ann Oncol. 19 (2008), 1082-1089.
  111. Beckmann MW, Blohmer JU, Costa SD, Diedrich K, Diel I, Eiermann W, Friese K, Gerber B, Harbeck N, Hilfrich J, Janni W, Jaenicke F, Jonat W, Kaufmann M, Kiechle M, Koehler U, Kreienberg R, von Minckwitz G, Moebus V, Nitz U, Schneeweiss A, Thomssen C, Wallwiener D: Zurich Consensus: German Expert Opinion on the St. Gallen Votes on 15 March 2009 (11th International Conference at St. Gallen: Primary Therapy of Early Breast Cancer). Breast Care (Basel) 4, (2009), 109-116.
  112. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke MJ, Weingart O, Kluge S, Piper M, Napoli M, Rades D, Steensma D, Djulbegovic B, Fey MF, Ray-Coquard I, Moebus V, Thomas G, Untch M, Schumacher M, Egger

M, Engert A.: Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data.  
Cochrane Database Syst Rev. 2009 Jul 8;(3):CD007303. Review.

113. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, Piper M, Rades D, Steensma DP, Djulbegovic B, Fey MF, Ray-Coquard I, Machtay M, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A.: Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.  
Lancet 373 (2009):1532-42.
114. Untch M, Möbus V, Kuhn W, Muck BR, Thomssen C, Bauerfeind I, Harbeck N, Werner C, Lebeau A, Schneeweiss A, Kahlert S, von Koch F, Petry KU, Wallwiener D, Kreienberg R, Albert US, Lück HJ, Hinke A, Jänicke F, Konecny GE: Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer.  
J Clin Oncol. 27 (2009), 2938-2945.
115. Pölcher M, Mahner S, Ortmann O, Hilfrich J, Diedrich K, Breitbach GP, Höss C, Leutner C, Braun M, Möbus V, Karbe I, Stimmeler P, Rudlowski C, Schwarz J, Kuhn W: Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer--a prospective multicenter phase II trial (PRIMOVAR).  
Oncol Rep. 22 (2009), 605-613.
116. Moebus V, Jackisch C, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Schneeweiss A, Huober J, Harbeck N, von Minckwitz G, Runnebaum IB, Hinke A, Kreienberg R, Konecny GE, Untch M.: Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.  
J Clin Oncol. 28 (2010), 2874-80.
117. Konecny GE, Pauletti G, Untch M, Wang HJ, Möbus V, Kuhn W, Thomssen C, Harbeck N, Wang L, Apple S, Jänicke F, Slamon DJ: Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer.  
Breast Cancer Res Treat. 120 (2010), 481-499.
118. Müller V, Thomssen C, Schmidt M, Glados M, Jackisch C, Heilmann V, Hinke A, Lehnert A, Borowicz H, Möbus V: Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer.  
BMC Cancer. 10 (2010), 430.
119. Harbeck N, Pegram MD, Rüschoff J, Möbus V: Targeted Therapy in Metastatic Breast Cancer: The HER2/neu Oncogene.  
Breast Care (Basel), 5(s1) (2010), 3-7.
120. Hofstetter G, Berger A, Fiegl H, Slade N, Zorić A, Holzer B, Schuster E, Mobus VJ, Reimer D, Daxenbichler G, Marth C, Zeimet AG, Concin N, Zeillinger R: Alternative splicing of p53 and p73: the novel p53 splice variant p53delta is an independent prognostic marker in ovarian cancer.  
Oncogene. 29 (2010), 1997-2004.

121. J.U. Blohmer, S. Paepke, J. Sehouli, D. Boehmer, M. Kolben, F. Würschmidt, U. Petry, R. Kimmig, D. Elling, C. Thomssen, G. v. Minckwitz, V. Möbus, A. Hinke, S. Kümmel, V. Budach, W. Lichtenegger, P. Schmid: Randomized Phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. *J. Clin. Oncol.* 29 (2011), 3791-3797
  
122. Loibl S, Mueller V, von Minckwitz G, Conrad B, Koehne CH, Kremers S, Forstbauer H, Linder M, Nekljudova V, Moebus V; GBG/AGO/NOGGO study groups: Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33). *Support Care Cancer.* 19 (2011), 1789-1795